Alzheimer disease and Down syndrome: factors in pathogenesis

Initial sequencing and analysis of the human genome

International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216 · see citing works

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · see citing works

Statins and the risk of dementia

Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,763 · see citing works

Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors

Wolozin, B. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,401 · see citing works

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · see citing works

Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model

Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J. J., Bryant‐Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 1,003 · see citing works

Intraneuronal Aβ42 Accumulation in Human Brain

Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · see citing works

Endocytic Pathway Abnormalities Precede Amyloid β Deposition in Sporadic Alzheimer’s Disease and Down Syndrome

Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gómez‐Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 832 · see citing works

The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease

Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., & Ashe, K. H. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01858.2002 · Cited by 714 · see citing works

Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation

Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · see citing works

Clearing the brain's amyloid cobwebs

Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541 · see citing works

A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Refolo, L. M., Pappolla, M. A., LaFrancois, J. J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M. H., Petanceska, S. S., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0422 · Cited by 521 · see citing works

Amyloid-β oligomers: their production, toxicity and therapeutic inhibition

Walsh, D. M., Klyubin, I. V., Fadeeva, J. V., Rowan, M. J., & Selkoe, D. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300552 · Cited by 507 · see citing works

The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome

Mann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471 · see citing works

Cholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains

Schindler, S. E., Das, P., Nyborg, A. C., McLendon, C., Shoji, M., Kawarabayashi, T., Younkin, L. H., Younkin, S. G., & Golde, T. E. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0470 · Cited by 426 · see citing works

Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome

Iwatsubo, T., Mann, D. M. A., Odaka, A., Suzuki, N., & Ihara, Y. (1995) · Annals of Neurology · doi:10.1002/ana.410370305 · Cited by 380 · see citing works

The pathological association between down syndrome and Alzheimer disease

Mann, D. M. A. (1988) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(88)90041-3 · Cited by 346 · see citing works

Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition

Dam, D. V., D’Hooge, R., Staufenbiel, M., Ginneken, C. J. V., Meir, F. V., & Deyn, P. P. D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02444.x · Cited by 297 · see citing works

The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol‐lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis

Palinski, W., & Claudio Napoli, A. (2002) · The FASEB Journal · doi:10.1096/fj.02-0226rev · Cited by 267 · see citing works

β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 259 · see citing works

Incidence And Course Of Dementia In People With Down's Syndrome: Findings From A Population‐Based Study

Holland, A. J., Hon, J., Huppert, F. A., & Stevens, F. (2000) · Journal of Intellectual Disability Research · doi:10.1046/j.1365-2788.2000.00263.x · Cited by 259 · see citing works

Intraneuronal Aβ42 accumulation in Down syndrome brain: Original Articles

Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., & Lemere, C. A. (2002) · Amyloid · doi:10.3109/13506120208995241 · Cited by 255 · see citing works

The neurobiologie consequences of down syndrome

Coyle, J. T., Oster-Granite, M. L., & Gearhart, J. D. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90074-2 · Cited by 248 · see citing works

Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome

Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248 · see citing works

Mortality and Cancer Incidence Among Individuals With Down Syndrome

Hill, D. A., Gridley, G., Cnattingius, S., Mellemkjær, L., Linet, M. S., Adami, H., Olsen, J. H., Nyrén, O., & Fraumeni, J. F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.705 · Cited by 247 · see citing works

<i>App</i>Gene Dosage Modulates Endosomal Abnormalities of Alzheimer's Disease in a Segmental Trisomy 16 Mouse Model of Down Syndrome

Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241 · cited 2× · see citing works

Rab5-stimulated Up-regulation of the Endocytic Pathway Increases Intracellular β-Cleaved Amyloid Precursor Protein Carboxyl-terminal Fragment Levels and Aβ Production

Grbovic, O. M., Mathews, P. M., Jiang, Y., Schmidt, S. D., Dinakar, R., Terio, N. B., Ceresa, B. P., Nixon, R. A., & Cataldo, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304122200 · Cited by 236 · see citing works

Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's Syndrome

Hof, P. R. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280065020 · Cited by 234 · see citing works

Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

Knauer, M. F., Soreghan, B., Burdick, D., Kosmoski, J., & Glabe, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7437 · Cited by 233 · see citing works

Intracellular Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease

Glabe, C. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:137 · Cited by 222 · see citing works

Down's syndrome: an atheroma-free model?

Murdoch, J. C., Rodger, J. C., Rao, S. S., Fletcher, C., & Dunnigan, M. G. (1977) · BMJ · doi:10.1136/bmj.2.6081.226 · Cited by 221 · see citing works

Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis

Leverenz, J. B., & Raskind, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6777 · Cited by 214 · see citing works

The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration

Melchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202 · see citing works

Genetic and host factors for dementia in Down's syndrome

Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188 · see citing works

Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease

Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187 · see citing works

Untitled work

(1997) · PubMed · Cited by 184 · see citing works

A fluid connection: Cholesterol and Aβ

Wolozin, B. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101123198 · Cited by 179 · see citing works

Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes

Krysiak, R. G., Okopie, B., & Herman, Z. S. (2003) · Drugs · doi:10.2165/00003495-200363170-00005 · Cited by 165 · see citing works

Precocious aging and dementia in patients with Down's syndrome.

Wisniewski, K. E., Howe, J., Williams, D. G., & Wisniewski, H. M. (1978) · PubMed · Cited by 153 · see citing works

Apolipoprotein E and Alzheimer Disease: An Update on Genetic and Functional Analyses

Saunders, A. M. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.9.751 · Cited by 148 · see citing works

Neuropathological Changes in Down's Syndrome Hippocampal Formation

Hyman, B. T. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280059019 · Cited by 147 · see citing works

Chromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease

Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 146 · see citing works

Clinical spectrum and molecular diagnosis of Angelman and Prader-Willi syndrome patients with an imprinting mutation

Saitoh, S., Buiting, K., Cassidy, S. B., Conroy, J. M., Driscoll, D. J., Gabriel, J. M., Gillessen‐Kaesbach, G., Glenn, C. C., Greenswag, L. R., Horsthemke, B., et al. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970120)68:2 · Cited by 137 · see citing works

Life-long overexpression of S100β in Down’s syndrome: implications for Alzheimer pathogenesis

Griffin, W. S. T., Sheng, J. G., McKenzie, J. E., Royston, M. C., Gentleman, S., Brumback, R. A., Cork, L. C., Bigio, M. R. D., Roberts, G. W., & Mrak, R. E. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00074-8 · Cited by 134 · see citing works

Phospholipid composition and levels are altered in down syndrome brain

Murphy, E. J., Schapiro, M. B., Rapoport, S. I., & Shetty, H. U. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02205-8 · Cited by 114 · see citing works

Earlier onset of Alzheimer's disease in men with Down syndrome

Schupf, N., Kapell, D., Nightingale, B., et al. (1998) · Neurology · doi:10.1212/wnl.50.4.991 · Cited by 113 · see citing works

Down's syndrome and atherosclerosis

Ylä‐Herttuala, S., Luoma, J. S., Nikkari, T., & Kivimäki, T. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90110-x · Cited by 110 · see citing works

Intracellular Accumulation of Insoluble, Newly Synthesized Aβn-42 in Amyloid Precursor Protein-transfected Cells That Have Been Treated with Aβ1–42

Yang, A. J., Chandswangbhuvana, D., Shu, T., Henschen, A., & Glabe, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20650 · Cited by 108 · see citing works

Complement Association with Neurons and β-Amyloid Deposition in the Brains of Aged Individuals with Down Syndrome

Head, E., Azizeh, B. Y., Lott, I. T., Tenner, A. J., Cotman, C. W., & Cribbs, D. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0380 · Cited by 103 · see citing works

Alzheimer dementia in Down's syndrome: the relevance of cognitive ability

Temple, V. K., Jozsvai, E., Konstantareas, M. M., & Hewitt, T. (2001) · Journal of Intellectual Disability Research · doi:10.1046/j.1365-2788.2001.00299.x · Cited by 78 · see citing works

Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome

Head, E., Garzon-Rodriguez, W., Johnson, J. K., Lott, I. T., Cotman, C. W., & Glabe, C. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0431 · Cited by 75 · see citing works

The Presence of Isoaspartic Acid in β-Amyloid Plaques Indicates Plaque Age

Fonseca, M. I., Head, E., Velázquez, P., Cotman, C. W., & Tenner, A. J. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7058 · Cited by 75 · see citing works

<i>APOE</i> ε4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome

Deb, S., Braganza, J., Norton, N., Williams, H., Kehoe, P. G., Williams, J., & Owen, M. J. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.5.468 · Cited by 71 · see citing works

Neuronal localization of C1q in preclinical Alzheimer's disease

Fonseca, M. I., Kawas, C. H., Troncoso, J. C., & Tenner, A. J. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.004 · Cited by 71 · see citing works

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease

Golde, T. E., & Eckman, C. B. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01965-1 · Cited by 64 · see citing works

Lipids and lipoproteins in persons with Down's syndrome

Pueschel, S. M., Craig, W. Y., & Haddow, J. E. (1992) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.1992.tb00535.x · Cited by 60 · see citing works

Cholesterol Modulates Amyloid Beta-peptide’s Membrane Interactions

Eckert, G. P., Kirsch, C., Leutz, S., Wood, W. G., & Müller, W. E. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-43059 · Cited by 59 · see citing works

Molecular Dating of Senile Plaques in the Brains of Individuals with Down Syndrome and in Aged Dogs

Azizeh, B. Y., Head, E., Ibrahim, M. A., Torp, R., Tenner, A. J., Kim, R. C., Lott, I. T., & Cotman, C. W. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7359 · Cited by 58 · see citing works

Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.

Shetty, H. U., Schapiro, M. B., Holloway, H. W., & Рапопорт, С. И. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117696 · Cited by 54 · see citing works

Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome

Hirayama, A., Horikoshi, Y., Maeda, M., Ito, M., & Takashima, S. (2003) · Brain and Development · doi:10.1016/s0387-7604(02)00209-7 · Cited by 45 · see citing works

DOES DOWN SYNDROME SUPPORT HOMOCYSTEINE THEORY OF ARTERIOSCLEROSIS?

Brattström, L. E., Englund, E. M., & Brun, A. E. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91772-7 · Cited by 45 · see citing works

Influence of the amyloid precursor protein locus on dementia in Down syndrome

Margallo‐Lana, M. L., Morris, C. M., GIBSON, A. M., Tan, A. L., Kay, D. W. K., Tyrer, S. P., Moore, B. P., & Ballard, C. G. (2004) · Neurology · doi:10.1212/01.wnl.0000129275.13169.be · Cited by 43 · see citing works

The impact of risk factors of Alzheimer's disease in the Down syndrome

Folin, M., Baiguera, S., Conconi, M. T., Pati, T., Grandi, C., Parnigotto, P., & Nussdorfer, G. G. (2003) · International Journal of Molecular Medicine · doi:10.3892/ijmm.11.2.267 · Cited by 43 · see citing works

Microglial cells and amyloid ? protein (A?) deposition: association with A?40-plaques

Mann, D. M. A., Iwatsubo, T., Fukumoto, H., Ihara, Y., Odaka, A., & Suzuki, N. (1995) · Acta Neuropathologica · doi:10.1007/bf00294808 · Cited by 40 · see citing works

Trisomy 21 is associated with hypercholesterolemia during intrauterine life

Bocconi, L., Nava, S., Fogliani, R., et al. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70544-1 · Cited by 38 · see citing works

Determinants of aggression, and adaptive and maladaptive behaviour in older people with Down’s syndrome with and without dementia

Cosgrave, M. P., Tyrrell, J., McCarron, M., et al. (1999) · Journal of Intellectual Disability Research · doi:10.1046/j.1365-2788.1999.043005393.x · Cited by 37 · see citing works

The 129 codon polymorphism of the Prion Protein gene influences earlier cognitive performance in Down syndrome subjects

Bo, R. D., Comi, G. P., Giorda, R., et al. (2003) · Journal of Neurology · doi:10.1007/s00415-003-1057-5 · Cited by 31 · see citing works

Detection of Alzheimer disease in individuals with Down syndrome.

Nelson, L., Lott, I. T., Touchette, P. E., et al. (1995) · PubMed · Cited by 30 · see citing works

Novel Risk Factors for Vascular Disease: The Homocysteine Hypothesis of Cardiovascular Disease

Wilcken, D. E. L. (1998) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679800500402 · Cited by 24 · see citing works

β-Amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome

Head, E., Lott, I. T., Cribbs, D. H., Cotman, C. W., & Rohn, T. T. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00705-x · Cited by 23 · see citing works

Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease

Wilcken, D. E. L. (1998) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199808000-00002 · Cited by 21 · see citing works

Relation between apolipoprotein E genotype, hepatitis b virus status, and thyroid status in a sample of older persons with down syndrome

Percy, M. E., Potyomkina, Z., Dalton, A. J., et al. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20099 · Cited by 20 · see citing works

Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease

Hopkins, W. E., Fukagawa, N. K., Sobel, B. E., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00864-4 · Cited by 19 · see citing works

Plaques and Tangles: Searching for Primary Events in a Forest of Data

Cummings, B. J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00049-3 · Cited by 16 · see citing works

Child abuse and the clinical course of drug misuse

Browne, R., & O’Connor, J. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.469 · Cited by 8 · see citing works

Apolipoprotein E, Alzheimer's disease and Down's syndrome

Prasher, V. P., & Haque, S. M. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.469-a · Cited by 7 · see citing works

Untitled work

(2002) · doi:10.1352/0895-8017(2002)107

Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging

Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638 · see citing works

At the interface of sensory and motor dysfunctions and Alzheimer’s disease.

Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589 · see citing works

Nurturing brain plasticity: Impact of environmental enrichment

Baroncelli, L., Braschi, C., Spolidoro, M., Begenisic, T., Sale, A., & Maffei, L. (2010) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2009.193 · Cited by 330 · see citing works

Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer’s disease

Jin, M., Xu, R., Wang, L., Alam, M. M., Ma, Z., Zhu, S., Martini, A. C., Jadali, A., Bernabucci, M., Xie, P., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.06.007 · Cited by 174 · see citing works

Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome

Contestabile, A., Benfenati, F., & Gasparini, L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.003 · Cited by 134 · see citing works

Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease

Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105 · see citing works

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease

Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97 · see citing works

Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease

Mann, D. M. A., Davidson, Y. S., Robinson, A. C., Allen, N., Hashimoto, T., Richardson, A., Jones, M., Snowden, J. S., Pendleton, N., Potier, M.-C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1866-3 · Cited by 73 · see citing works

Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial

Rafii, M. S., Sol, O., Mobley, W. C., Delpretti, S., Skotko, B. G., Burke, A. D., Sabbagh, M. N., Yuan, S. H., Rissman, R. A., Pulsifer, M., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0983 · Cited by 52 · see citing works

Proteomic identification of specifically carbonylated brain proteins in APPNLh/APPNLh×PS-1P264L/PS-1P264L human double mutant knock-in mice model of Alzheimer disease as a function of age

Sultana, R., Robinson, R. A. S., Di Domenico, F., Abdul, H. M., Clair, D. K. S., Markesbery, W. R., Cai, J., Pierce, W. M., & Butterfield, D. A. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.06.015 · Cited by 41 · see citing works

Progress and challenges in the diagnosis of dementia: a critical review

Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31 · see citing works

The Current Status of Neuropathology in the Federal Republic of Germany 1979

Peiffer, J. (1979) · Pathology - Research and Practice · doi:10.1016/s0344-0338(79)80036-9 · Cited by 2 · see citing works

Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons

Hoffman, L. B., Schmeidler, J., Lesser, G. T., Beeri, M. S., Purohit, D. P., Grossman, H. T., & Haroutunian, V. (2009) · Neurology · doi:10.1212/01.wnl.0000345881.82856.d5 · Cited by 159 · see citing works

Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms

Guerrero‐Berroa, E., Schmeidler, J., & Beeri, M. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.01.019 · Cited by 14 · see citing works

Perspectives in neuropathology

Haymaker, W. (1961) · Acta Neuropathologica · doi:10.1007/bf00687188 · Cited by 2 · see citing works

Late-Onset Alzheimer Disease Neuropathology Genomic Screen Identifies Novel Loci For Neuritic Plaque And Other AD Neuropathology Features (I5-2.001)

Beecham, G. W., Hamilton, K., Schellenberg, G. D., Pericak‐Vance, M. A., & Montine, T. J. (2014) · Neurology · doi:10.1212/wnl.82.10_supplement.i5-2.001